See page five Lobbying Issues: molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs
CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding
comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues
HR 436/ S 17, Protect Medical Innovation Act of 2011
HR 488, Save Our Medical Devices Act of 2011
HR 755, Investing in Our Future Act of 2011
HR 965/ S 1211, Preservation of Antibiotics for Medical Treatment Act of 2011
HR 2182 Generating Antibiotic Incentives Now (GAIN)
S 660, Preserving Access to Targeted, Individualized, and Effective New Treatments and Services (PATIENTS) Act of 2011 See page three Lobbying Issues: molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs
CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding
comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues
HR 436/ S 17, Protect Medical Innovation Act of 2011
HR 488, Save Our Medical Devices Act of 2011
HR 755, Investing in Our Future Act of 2011
HR 965/ S 1211, Preservation of Antibiotics for Medical Treatment Act of 2011
HR 2182 Generating Antibiotic Incentives Now (GAIN)
S 660, Preserving Access to Targeted, Individualized, and Effective New Treatments and Services (PATIENTS) Act of 2011 See page 7 Lobbying Issues: molecular diagnostic tests, infection control and prevention programs (Multidrug resistant organisms (MDRO)), CDC-related issues (MDRO research and surveillance), hospital and other provider quality improvement programs
CMS-related issues (reimbursement and coverage policies), FDA oversight, global health funding
comparative effectiveness, personalized medicine/pharmacogenomics, Veterans Affairs healthcare-related issues
HR 436/ S 17, Protect Medical Innovation Act of 2011
HR 488, Save Our Medical Devices Act of 2011
HR 755, Investing in Our Future Act of 2011
HR 965/ S 1211, Preservation of Antibiotics for Medical Treatment Act of 2011
HR 2182 Generating Antibiotic Incentives Now (GAIN)
S 660, Preserving Access to Targeted, Individualized, and Effective New Treatments and Services (PATIENTS) Act of 2011
MED - Medical/Disease Research/Clinical Labs HCR - Health Issues MMM - Medicare/Medicaid
132 - Agency for Healthcare Research & Quality (AHRQ) 134 - Centers For Disease Control & Prevention (CDC) 136 - Centers For Medicare and Medicaid Services (CMS) 135 - Food & Drug Administration (FDA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 253 - Medicare Payment Advisory Commission (MedPAC) 139 - Natl Institutes of Health (NIH) 1 - SENATE 132 - Agency for Healthcare Research & Quality (AHRQ) 134 - Centers For Disease Control & Prevention (CDC) 136 - Centers For Medicare and Medicaid Services (CMS) 135 - Food & Drug Administration (FDA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 253 - Medicare Payment Advisory Commission (MedPAC) 139 - Natl Institutes of Health (NIH) 1 - SENATE 132 - Agency for Healthcare Research & Quality (AHRQ) 134 - Centers For Disease Control & Prevention (CDC) 136 - Centers For Medicare and Medicaid Services (CMS) 135 - Food & Drug Administration (FDA) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 253 - Medicare Payment Advisory Commission (MedPAC) 139 - Natl Institutes of Health (NIH) 1 - SENATE
CEPHEID
2200 Pennsylvania Ave NW, Suite 800 W, Washington, DC, DC, 20037, US
MICHELE M SCHOONMAKER HALLIE CHRISTINE LEWIS MICHELE M SCHOONMAKER HALLIE CHRISTINE LEWIS MICHELE M SCHOONMAKER HALLIE CHRISTINE LEWIS